Consumables was Zomedica’s largest segment in fiscal 2025, bringing in $17.84M of $28.17M (63%).
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Consumables | $11.07M | $15.55M | $16.37M | $17.84M | |
| Capital | $7.34M | $8.18M | $8.35M | $8.23M | |
| Trodes | — | — | — | — | |
| Engineering | — | — | — | $1.98M | |
| Instruments | — | — | — | — | |
| Other | $136.00K | $85.00K | $131.00K | $123.00K | |
| Other Revenue | — | — | — | — | |
| Total | $18.54M | $23.81M | $24.85M | $28.17M |
Zomedica brought in $28.17M from its four segments in fiscal 2025, the year ended December 31, 2025. That is less than the $32.03M it reports by geography, so these segments do not cover all of its revenue. Consumables was the largest at $17.84M (63.3%), ahead of Capital at $8.23M (29.2%) and Engineering at $1.98M (7.0%). The remaining segment, Other, brought in $123.00K.
Compared with fiscal 2024, Consumables grew 9.0% to $17.84M, while Capital fell 1.5% to $8.23M. Some of that change comes from Zomedica regrouping its segments.
Zomedica began breaking out Engineering in fiscal 2025, when it brought in $1.98M.
Therapeutic Devices was Zomedica’s largest segment in fiscal 2025, bringing in $17.84M of $21.93M (81%).
| Statement Business Segments | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Therapeutic Devices | $11.07M | $15.55M | $16.37M | $17.84M | |
| Therapeutics | — | — | — | — | |
| Development Services | — | — | — | $1.98M | |
| Diagnostics | $391.00K | $768.00K | $1.30M | $2.11M | |
| Total | $11.46M | $16.31M | $17.66M | $21.93M |
Zomedica brought in $21.93M from its three segments in fiscal 2025, the year ended December 31, 2025. That is less than the $32.03M it reports by geography, so these segments do not cover all of its revenue. Therapeutic Devices was the largest at $17.84M (81.4%), ahead of Diagnostics at $2.11M (9.6%) and Development Services at $1.98M (9.0%).
Compared with fiscal 2024, Diagnostics grew 63.1% to $2.11M and Therapeutic Devices grew 9.0% to $17.84M. Some of that change comes from Zomedica regrouping its segments.
Zomedica began breaking out Development Services in fiscal 2025, when it brought in $1.98M.
Us was Zomedica’s largest region in fiscal 2025, bringing in $26.46M of $32.03M (83%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Us | $20.68M | $22.56M | $26.46M |
| Foreign Countries | $4.50M | $4.73M | $5.57M |
| Total | $25.19M | $27.29M | $32.03M |
Zomedica brought in $32.03M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 17.4% from $27.29M in fiscal 2024. Us was the largest at $26.46M (82.6%), ahead of Foreign Countries at $5.57M (17.4%).
Compared with fiscal 2024, Foreign Countries grew 17.8% to $5.57M and Us grew 17.3% to $26.46M. From fiscal 2023 to 2025, combined revenue from these regions grew from $25.19M to $32.03M, a compound annual growth rate of 12.8%. Us' share held steady at about 82.6%.
Zomedica (ZOMDF) reports its revenue by segment, by statement business segments and by geography. In fiscal 2025, Consumables was its largest segment, bringing in $17.84M (63.3% of the total), followed by Capital at $8.23M (29.2%).
Consumables was Zomedica's largest segment in fiscal 2025, bringing in $17.84M, or 63.3% of the $28.17M total across its four segments.
Us was Zomedica's largest region in fiscal 2025, bringing in $26.46M, or 82.6% of the $32.03M total across its two regions.
Foreign Countries grew faster than Us in fiscal 2025, up 17.8% from $4.73M to $5.57M. Us grew 17.3% to $26.46M.
Every figure comes from Zomedica's annual financial filings, as reported. Each line keeps the name Zomedica gives it, and years follow its fiscal calendar.
Zomedica's revenue by segment goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.